Dr. Amit Kulkarni, MD
Claim this profileUniversity of Minnesota
Affiliated Hospitals
University Of Minnesota
Clinical Trials Amit Kulkarni, MD is currently running
RMT
for Colitis
Immune-related colitis from immune checkpoint inhibitors (ICI) is a common adverse effect causing significant morbidity and impairment of quality of life (QoL). Steroids are the first line of treatment for severe ICI induced Immune- mediated diarrhea and colitis (IMDC). If there is no improvement in 48 to 72 hours, other immunosuppressive agents (infliximab, vedolizumab) are recommended. However, efficacy data supporting the use of immunosuppressives for steroid refractory IMDC is limited by case reports/series. Clinical trials focusing on steroid-refractory colitis are sparse. Novel treatments for IMDC outside of blanket immunosuppression are needed. There is robust evidence to suggest that gut microbial diversity and composition is associated with both ICI efficacy and toxicity. Preliminary studies have shown that pathophysiology of immune mediated colitis may be related to loss of gut microbial diversity. Recently, multiple case series have shown the utility of fecal microbiota transplant for treatment of refractory IMDC providing the proof of concept. This is a pilot randomized placebo controlled study to assess the safety and feasibility of oral restorative microbiota therapy (RMT) in patients with steroid- refractory IMDC.
Recruiting
0 awards
Phase 2
Pembrolizumab
for Early-Stage Non-Small Cell Lung Cancer
A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm. Patients will be randomized (1:1) 4-12 weeks following surgery to either: * Arm A: Pembrolizumab 400 mg every 6 weeks × 9 cycles * Arm B: Observation Stratification factors will include: PD-L1 TPS (\<50% vs. ≥50%), and tumor size (1-2 cm vs. \>2-4 cm)
Recruiting
1 award
Phase 2
5 criteria
More about Amit Kulkarni, MD
Clinical Trial Related
1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Amit Kulkarni, MD has experience with
- Placebo
- RMT
- Pembrolizumab
Breakdown of trials Amit Kulkarni, MD has run
Psychogenic Colitis
Inflammatory Bowel Disease
Colitis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Amit Kulkarni, MD specialize in?
Amit Kulkarni, MD focuses on Psychogenic Colitis and Inflammatory Bowel Disease. In particular, much of their work with Psychogenic Colitis has involved Stage IV patients, or patients who are undergoing treatment.
Is Amit Kulkarni, MD currently recruiting for clinical trials?
Yes, Amit Kulkarni, MD is currently recruiting for 2 clinical trials in Minneapolis Minnesota. If you're interested in participating, you should apply.
Are there any treatments that Amit Kulkarni, MD has studied deeply?
Yes, Amit Kulkarni, MD has studied treatments such as Placebo, RMT, Pembrolizumab.
What is the best way to schedule an appointment with Amit Kulkarni, MD?
Apply for one of the trials that Amit Kulkarni, MD is conducting.
What is the office address of Amit Kulkarni, MD?
The office of Amit Kulkarni, MD is located at: University of Minnesota, Minneapolis, Minnesota 55414 United States. This is the address for their practice at the University of Minnesota.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.